Bangalore-based biotech company Connexios Life Sciences, and Boehringer Ingelheim announced an exclusive global research collaboration agreement for AMPK for the treatment of patients with type-2 diabetes.
The terms and financial details of the collaboration were undisclosed.
As part of the agreement, Boehringer Ingelheim obtains global rights to CNX-012, Connexios Life Sciences' program on AMPK activators.
The program includes CNX-570 and other compounds which are in early pre-clinical development.
Boehringer Ingelheim will be responsible for all further development and commercialization of the candidates from the AMPK program.
"As a pure research-driven organization from India, we believe that the agreement with Boehringer Ingelheim is a big validation of both our scientific approach and capabilities as well as of our business model," commented Mr Suri Venkatachalam, CEO and founder, Connexios.
CNX-012 is Connexioss' flagship program which leverages Network Biology approach and platform.
Commenting on the agreement, Mr Michel Pairet, Senior VP and R&D global head, Boehringer Ingelheim said, "We are extremely pleased to enter into this agreement with Connexios, a company recognized as experts in their field, which will further strengthen our discovery and development efforts in the area of cardiometabolic diseases."
